Wyeth Alavert Contributes $8.5 Mil. To Q4 Consumer Health Revenue
This article was originally published in The Tan Sheet
Wyeth Consumer Healthcare recorded almost $8.5 mil. in Alavert sales during the fourth quarter of 2002
You may also be interested in...
Wyeth Consumer Healthcare is staking a claim to the OTC loratadine market with Alavert pricing of 56¢ to $1 per orally disintegrating tablet and high-value coupons
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning